Unknown

Dataset Information

0

Impact of a novel prognostic model, hematopoietic cell transplant-composite risk (HCT-CR), on allogeneic transplant outcomes in patients with acute myeloid leukemia and myelodysplastic syndrome.


ABSTRACT: Outcomes after allogeneic stem-cell transplantation (AHSCT) are influenced by both disease- and patient-related factors. Here, we developed a novel prognostic model, hematopoietic cell transplant-composite risk (HCT-CR), by combining the refined disease risk index (DRI-R) and hematopoietic stem-cell transplant comorbidity/age index (HCT-CI/Age) to predict post-transplant survival for patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). The analysis included 942 AML/MDS patients treated with AHSCT. Patients were stratified into 4 HCT-CR risk groups: Low-risk-patients with low/intermediate DRI-R and HCT-CI/Age??3 (N?=?272); Intermediate-risk-patients with low/intermediate DRI-R and HCT-CI/Age?>3 (N?=?168); High-risk-patients with high/very high DRI-R and HCT-CI/Age??3 (N?=?284); and Very high-risk-patients with high/very high DRI-R and HCT-CI/Age?>3 (N?=?184). Compared with the low-risk group, intermediate, high, and very high-risk groups had a significantly increased risk of death [adjusted HR of 1.37 (P?

SUBMITTER: Kongtim P 

PROVIDER: S-EPMC7285649 | BioStudies | 2019-01-01

REPOSITORIES: biostudies

Similar Datasets

2017-01-01 | S-EPMC6857174 | BioStudies
2014-01-01 | S-EPMC3996925 | BioStudies
2020-01-01 | S-EPMC7556156 | BioStudies
2013-01-01 | S-EPMC3525761 | BioStudies
2015-01-01 | S-EPMC4578937 | BioStudies
1000-01-01 | S-EPMC3744995 | BioStudies
2013-01-01 | S-EPMC3805928 | BioStudies
2017-01-01 | S-EPMC5226883 | BioStudies
1000-01-01 | S-EPMC6142436 | BioStudies
2017-01-01 | S-EPMC5691091 | BioStudies